Get Ahead with IPO Insights, IPO Prophet

IPO Prophet

Get Ahead with IPO Insights

At IPO Prophet®, our team leverages over three decades of expertise to deliver actionable quantitative analytics for the IPO market in real-time. This platform synthesizes our extensive experience investing in IPOs, providing investors with revolutionary tools to navigate the complexities of issuance day. Our mission is to empower investors with data-driven insights to make more informed decisions.

Equity Capital Markets

<ul><li>One qualifying IPO priced and began trading this week: TRex Bio raised $116.7 million.</li><li>It priced at the low end of its range, opened below issue, recovered to a double-digit intraday premium and closed exactly at the $14.00 issue price.</li><li>The result kept the financing window open for biotech, but it did not demonstrate broad risk appetite.</li></ul>

One qualifying IPO priced and began trading this week: TRex Bio raised $116.7 million.It priced at the low end of its range, opened below issue, recovered to a double-digit intraday premium and closed exactly at the $14.00 issue price.The result kept the financing window open for biotech, but it did not demonstrate broad risk appetite.

US IPOs and Secondary Offerings, IPO Boutique

IPO Boutique

US IPOs and Secondary Offerings

For more than 20 years, we have been providing research, analysis, commentary and ratings on US Equity Capital Markets to institutional investors (US IPOs and Secondary Offerings). Our vast network of contacts across the Equity Capital Markets and attention-to-detail sets us apart from our competitors.

Since 2012, we have achieved a successful hit rating on 89% of Buy-rated IPOs. The collective “Buy” ratings averaged a first trade of 16.3% above issue.Our Neutral Rated Deals averaged just 2% above the issue price at first trade.

Our written research includes pre-IPO notes before the deal is launched, follow-up analysis once the deal is live and post-listing trading analysis as well.

In addition, we provide a high-touch premium desk access which includes analyst access, as well as real time insights on US IPOs as well as secondary offerings.

IPOs and Secondary Offerings

<ul>
<li>TRex Bio priced 8.34 million shares at $14, opened down 3.6% and closed flat to issue after a subdued first session.</li>
<li>The book finished multiple times oversubscribed, but the top 10 accounts received 80% of the offering.</li>
<li>Biotech IPOs Can Still Attract Demand, but First-Day Premiums Remain Elusive as Broader Market Sentiment Influences Trading.</li>
</ul>


TRex Bio priced 8.34 million shares at $14, opened down 3.6% and closed flat to issue after a subdued first session.
The book finished multiple times oversubscribed, but the top 10 accounts received 80% of the offering.
Biotech IPOs Can Still Attract Demand, but First-Day Premiums Remain Elusive as Broader Market Sentiment Influences Trading.


TRex Bio (TRXB): TRex Bio Closes Flat as Oversubscribed Book Fails to Deliver IPO Pop

<ul>
<li>TRex Bio is seeking a $384–$439 million market cap, offering investors exposure to a clinical-stage platform targeting tissue Tregs across autoimmune and inflammatory diseases.</li>
<li>Eli Lilly provides meaningful validation, with a 23.8% pre-IPO stake and an anchor order allowing it to maintain up to 19.9%.</li>
<li>TRB-061 is the key near-term catalyst, with Phase 1b data in atopic dermatitis expected in mid-2027</li>
</ul>


TRex Bio is seeking a $384–$439 million market cap, offering investors exposure to a clinical-stage platform targeting tissue Tregs across autoimmune and inflammatory diseases.
Eli Lilly provides meaningful validation, with a 23.8% pre-IPO stake and an anchor order allowing it to maintain up to 19.9%.
TRB-061 is the key near-term catalyst, with Phase 1b data in atopic dermatitis expected in mid-2027


TRex Bio (TRXB): TRex Brings Treg Science to a Still-Open Biotech IPO Window

Smartkarma AI IPO Databooks, Smartkarma

αSK IPO Databooks

Smartkarma AI IPO Databooks

Smartkarma

Smartkarma unites the fragmented investment industry, connecting institutional investors, independent research providers, and corporates within a single network.

Research Reinvented

<ul><li><a href="https://smartkarma.com/entities/trex-bio" target="_blank">TRex Bio</a>, Inc. is a clinical-stage biopharmaceutical company focused on tissue Treg biology for immunoregulatory medicines to restore immune balance and promote tissue repair.</li><li>The company has TRB-061 in Phase 1a/b for atopic dermatitis, TRB-071 in IND-enabling studies, and TRB-051 in Phase 2a via a Lilly collaboration.</li><li>The company reported collaboration revenue of $39,108 thousand for FY2024, but also a net loss of $(29,308) thousand for six months ended June 30, 2026.</li></ul><p><em>This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.</em></p>

TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on tissue Treg biology for immunoregulatory medicines to restore immune balance and promote tissue repair.The company has TRB-061 in Phase 1a/b for atopic dermatitis, TRB-071 in IND-enabling studies, and TRB-051 in Phase 2a via a Lilly collaboration.The company reported collaboration revenue of $39,108 thousand for FY2024, but also a net loss of $(29,308) thousand for six months ended June 30, 2026.This content is AI-generated and displayed for general informational purposes only. Please verify independently before use.

IPO Databook: TRex Bio (TRXB US) - Oct 2026

<ul><li>✓ IPO Prophet Rating: 7.50/10 🏦 Deal Quality &amp; Underwriters: 8.20/10. TRex Bio is offering 8.33 million all-primary shares at $14.00-$16.00, targeting approximately $125 million at the midpoint, with Nasdaq trading under TRXB expected after pricing on October 9, 2026.</li><li>J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush provide a strong healthcare-focused underwriting group.</li><li>Deal quality is reinforced by collaborations with Eli Lilly and Janssen, backing from established biotechnology investors and Lilly’s non-binding indication of interest in purchasing approximately $13 million of the offering.</li></ul>

✓ IPO Prophet Rating: 7.50/10 🏦 Deal Quality &amp; Underwriters: 8.20/10. TRex Bio is offering 8.33 million all-primary shares at $14.00-$16.00, targeting approximately $125 million at the midpoint, with Nasdaq trading under TRXB expected after pricing on October 9, 2026.J.P. Morgan, Evercore ISI, Cantor, Stifel and Wedbush provide a strong healthcare-focused underwriting group.Deal quality is reinforced by collaborations with Eli Lilly and Janssen, backing from established biotechnology investors and Lilly’s non-binding indication of interest in purchasing approximately $13 million of the offering.

United States

A clinical-stage biopharmaceutical company building on regulatory T cell (Treg) biology

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

TRex Bio (TRXB US)

U.S. IPO Recap Week of 10/9/2026

Period: Week ended October 9, 2026. Coverage: Traditional U.S. operating-company IPOs of at least $100 million. One qualifying...

IPO Prophet

TRex Bio (TRXB): TRex Bio Closes Flat as Oversubscribed Book Fails to Deliver IPO Pop

TRex Bio closed flat at $14 after opening down 3.6%. Despite multiple...

IPO Boutique

TRex Bio (TRXB): TRex Brings Treg Science to a Still-Open Biotech IPO Window

TRex Bio brings a Treg-focused biotech platform to market with Lilly backing, Phase 1 clinical catalysts and early demand as biotech remains the...

IPO Boutique

IPO Databook: TRex Bio (TRXB US) - Oct 2026

TRex Bio, Inc. is a clinical-stage biopharmaceutical company focused on tissue Treg biology for immunoregulatory medicines to restore immune...

αSK IPO Databooks

IPO Rating: TRex Bio, Inc.

✓ IPO Prophet Rating: 7.50/10 🏦 Deal Quality & Underwriters: 8.20/10 TRex Bio is offering 8.33 million all-primary shares at $14.00-$16.00,...

IPO Prophet

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)